Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine (reduced antigen content)
- Development stage
- Phase 2
- Lead developer
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination vaccine, developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS), is designed for booster immunization against tetanus, diphtheria, and pertussis in individuals aged 6 years and older. It utilizes a reduced-antigen formulation (Tdap), which contains lower concentrations of diphtheria toxoid and pertussis antigens compared to pediatric DTaP vaccines. This approach is intended to maintain protective immunity while minimizing the frequency and severity of injection-site reactions and other adverse events in older populations. The vaccine is adsorbed onto an aluminum-based adjuvant to enhance the immune response. It is currently undergoing Phase I/II clinical evaluation to assess its safety and immunogenicity across different age groups.
- Other names
- Tdap vaccine (reduced antigen content)Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content)IMBCAMS Tdap
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine (reduced antigen content).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine (reduced antigen content).